News & Updates

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with colchicine does not appear to improve functional capacity, respiratory function, or inflammatory markers in adults with long COVID, as shown in a study.

Children hospitalized with acute SARS-CoV-2 and multisystem inflammatory syndrome (MIS) tend to experience neurologic manifestations, according to a study in Indonesia.

Influenza vaccination appears to provide a protective benefit against acute kidney injury (AKI) in older adults, according to a study.

Faecal microbiota transplantation has been shown to help resolve recurrent urinary tract infections in a small study.

Several factors may influence the development of Kawasaki disease (KD) in children, and these include delivery type and birth weight, among others.

Three formulations of the 21-valent pneumococcal conjugate vaccine (PCV21) have shown favourable immunogenicity and acceptable tolerability profile among toddlers and infants, when compared with PCV13, in a phase II study.

The investigational oral antiviral ensitrelvir shows potent antiviral activity in COVID-19, although its effect is slightly weaker than that of ritonavir-boosted nirmatrelvir, according to the ongoing, phase II, randomized controlled, adaptive pharmacometric platform PLATCOV trial.